21950-36-7

Basic information

• Product Name: Adenosine, 5'-aMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-
• Synonyms: Adenosine, 5'-aMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-;9-((3aR,4S,6R,6aR)-6-(aMinoMethyl)-2,2-diMethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-aMine;5'-AMino-5'-deoxy-2',3'-O-isopropylidineadenosine;5'-AMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-adenosine;Adenosine,5`-deoxy-2`3`-O-(1-Methylethylidene)-;5'-Amino-5'-O-(1-methylethylidene)-adenosine;9-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine
• CAS NO: 21950-36-7
• Molecular Formula: C₁₃H₁₈N₆O₃
• Molecular Weight: 306.32042
• Mol File: 21950-36-7.mol
• Article Data: 39

Chemical Properties

• Melting Point: 202-203℃
• Boiling Point: 553.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.80±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.08±0.29(Predicted)
• CAS DataBase Reference: Adenosine, 5'-aMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-(CAS DataBase Reference)
• NIST Chemistry Reference: Adenosine, 5'-aMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-(21950-36-7)
• EPA Substance Registry System: Adenosine, 5'-aMino-5'-deoxy-2',3'-O-(1-Methylethylidene)-(21950-36-7)

Safety Data

• Hazardous Substances Data: 21950-36-7(Hazardous Substances Data)

Upstream product

• 40982-79-4 N⁶,N⁶-dibenzoyl-5'-O-mesyl-2',3'-O-isopropylidene adenosine 
• 24514-56-5 9-((3aR,4R,6S,6aS)-6-(chloromethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 
• 58-61-7 adenosine 
• 40653-96-1 N⁶-benzoyl-2',3'-O-isopropylidene-5'-O-methylsulfonyladenosine 
• 68144-26-3 5'-azido-5'-deoxy-N⁶-benzoyl-2',3'-O-isopropylidene adenosine 
• 68179-90-8 ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl methanesulfonate 
• 5605-63-0 ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 
• 78111-39-4 5'-diphenylphosphate-5'-deoxy-2',3'-isopropylidene adenosine 
• 362-75-4 2',3'-isopropylidene adenosine 
• 39947-04-1 N-6-benzoyl-2',3'-O-isopropylideneadenosine 
• 39947-05-2 ((3aR,4R,6R,6aR)-6-(6-benzamido-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 
• 34245-48-2 5'-azido-5'-deoxy-2',3'-O-isopropylidene adenosine 
• 80860-44-2 2-[[(3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methyl]-2,3-dihydro-1H-isoindol-1,3-dione 
• 72525-45-2 5'-azido-5'-deoxy-2',3'-O-isopropylideneadenosine N¹-oxide 

Downstream Products

• 162757-17-7 1-(5'-deoxy-2',3'-O-isopropylidene adenosin-5'-yl)-2-methyl-3-phenylsulfonylisothiourea 
• 100-02-7 4-nitro-phenol 
• 32077-99-9 5'-deoxy-5'-acetamido-2',3'-O-isopropylidene adenosine 
• 116700-92-6 9-((3aR,4R,6R,6aR)-6-((ethylamino)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 
• 1381760-60-6 C₂₃H₂₉N₇O₅ 
• 366454-11-7 Pentanedioic acid [(3aR,4R,6R,6aR)-6-(6-amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl]-amide (1-oxo-2,3-dihydro-1H-isoindol-4-yl)-amide 
• 366454-10-6 N-[6-(6-amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl]-N'-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)-succinamide 
• 357928-44-0 [(3aR,4R,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl]-carbamic acid vinyl ester 

Relevant articles and documents

Methionyl adenylate analogues as inhibitors of methionyl-tRNA synthetase

Four stable analogues of methionyl adenylate (3-6) were designed as inhibitors of methionyl-tRNA synthetase and synthesized from 2',3'- isopropylideneadenosine. They strongly inhibited aminoacylation activity of methionyl-tRNA synthetases isolated from Escherichi coli, Mycobacterium tuberculosis, Saccharomyces cerevisiae and human. Among the microorganisms tested, however, these chemicals showed the growth inhibition effect only on E. coli.

Synthesis and evaluation of adenosine containing 3-arylfuran-2(5H)-ones as tyrosyl-tRNA synthetase inhibitors

Tyrosyl-tRNA synthetase (TyrRS) is an aminoacyl-tRNA synthetase family protein that possesses an essential role in bacterial protein synthesis. The synthesis, structure-activity relationship, and evolution of a novel series of adenosine-containing 3-arylfuran-2(5H)-ones as TyrRS inhibitors are described. Advanced compound d3 from this series exhibited excellent affinity for TyrRS with IC50 of 0.61?±?0.04?μM. Bacterial growth inhibition assays demonstrated that d3 showed submicromolar antibacterial potency against Escherichia coli and Pseudomonas aeruginosa, and compared to the marketed antibiotics ciprofloxacin.

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

Purine derivative and preparation method and application thereof

The invention discloses a purine derivative and a preparation method and application thereof, belongs to the technical field of medicines, and designs and synthesizes a series of purine derivatives and optical isomers, pharmaceutically acceptable salts, solvates or prodrugs of the purine derivatives. Experiments show that the compound has outstanding anti-cell proliferation activity and DOT1L enzyme inhibition effect, shows good tumor growth inhibition activity in a tumor transplantation tumor model, and has a good application prospect.

Biosynthesis, Mechanism of Action, and Inhibition of the Enterotoxin Tilimycin Produced by the Opportunistic Pathogen Klebsiella oxytoca

Tilimycin is an enterotoxin produced by the opportunistic pathogen Klebsiella oxytoca that causes antibiotic-associated hemorrhagic colitis (AAHC). This pyrrolobenzodiazepine (PBD) natural product is synthesized by a bimodular nonribosomal peptide synthetase (NRPS) pathway composed of three proteins: NpsA, ThdA, and NpsB. We describe the functional and structural characterization of the fully reconstituted NRPS system and report the steady-state kinetic analysis of all natural substrates and cofactors as well as the structural characterization of both NpsA and ThdA. The mechanism of action of tilimycin was confirmed using DNA adductomics techniques through the detection of putative N-2 guanine alkylation after tilimycin exposure to eukaryotic cells, providing the first structural characterization of a PBD-DNA adduct formed in cells. Finally, we report the rational design of small-molecule inhibitors that block tilimycin biosynthesis in whole cell K. oxytoca (IC50 = 29 ± 4 μM) through the inhibition of NpsA (KD = 29 ± 4 nM).